Tenders Are Invited For Medicinal Product For Autologous Cell Therapy - Axikabtagen Ciloleucel- 2025 in Czech Republic

Work Detail

Medicinal Product For Autologous Cell Therapy - Axikabtagen Ciloleucel- 2025. The Subject Of The Public Contract Is The Supply Of A Medicinal Product Intended For The Therapy Of Malignant Blood Diseases In The Total Expected Volume Of 32 Individual Doses Of The Medicinal Product. The Preparation Is Intended For The Provision Of Health Care At The Medical Workplace Of The Fn Plzeň. Deliveries Of The Subject Of Performance Will Be Carried Out On The Basis Of The Results Of The Completed Procurement Procedure For A Period Of Four Years From The Signing Of The Purchase Contract. Cytostatic Agent For Car-T Therapy (Axicabtagen Ciloleucel) - Infusion Bag Containing A Cell Dispersion Of 0.4 - 2X10^8 Viable Anti-Cd19 Car-Positive T-Lymphocytes. Estimated Annual Volume Is 8 Infusion Bags Containing An Individually Determined Amount Of The Active Ingredient, Atc L01xl03

Contact Information